BRPI0922871A2 - metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos - Google Patents

metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos

Info

Publication number
BRPI0922871A2
BRPI0922871A2 BRPI0922871A BRPI0922871A BRPI0922871A2 BR PI0922871 A2 BRPI0922871 A2 BR PI0922871A2 BR PI0922871 A BRPI0922871 A BR PI0922871A BR PI0922871 A BRPI0922871 A BR PI0922871A BR PI0922871 A2 BRPI0922871 A2 BR PI0922871A2
Authority
BR
Brazil
Prior art keywords
methods
multiple sclerosis
treating multiple
tetracyclic pyrazinoindoles
pyrazinoindoles
Prior art date
Application number
BRPI0922871A
Other languages
English (en)
Portuguese (pt)
Inventor
Andreas Persidis
Spyros Deftereos
Original Assignee
Biovista Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovista Inc filed Critical Biovista Inc
Publication of BRPI0922871A2 publication Critical patent/BRPI0922871A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0922871A 2008-12-11 2009-12-11 metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos BRPI0922871A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12157408P 2008-12-11 2008-12-11
US23323509P 2009-08-12 2009-08-12
PCT/US2009/067673 WO2010068867A1 (en) 2008-12-11 2009-12-11 Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles

Publications (1)

Publication Number Publication Date
BRPI0922871A2 true BRPI0922871A2 (pt) 2016-11-16

Family

ID=42243090

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922871A BRPI0922871A2 (pt) 2008-12-11 2009-12-11 metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos

Country Status (9)

Country Link
US (1) US20110268699A1 (enExample)
EP (1) EP2375900B1 (enExample)
JP (1) JP2012512165A (enExample)
CN (1) CN102395275A (enExample)
AU (1) AU2009324495B2 (enExample)
BR (1) BRPI0922871A2 (enExample)
CA (1) CA2747235C (enExample)
IL (1) IL213476A0 (enExample)
WO (1) WO2010068867A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2340254B8 (en) 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
EP2701696B1 (en) 2011-04-26 2020-06-03 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
HK1218251A1 (zh) * 2013-02-15 2017-02-10 Teva Pharmaceutical Industries Ltd. 用拉喹莫德治疗多发性硬化症
KR101521807B1 (ko) * 2014-01-20 2015-05-20 한국전자통신연구원 데이터 전송 제어 장치 및 그 방법
EP3831385B1 (en) * 2014-05-09 2024-07-10 Tecnimede Sociedade Tecnico-Medicinal S.A. Mandelate salts of pirlindole enantiomers for use in medicine
CN113214084A (zh) 2015-11-23 2021-08-06 乐巢拓普有限公司 1,4-二烯体系的位点特异性同位素标记
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
EP3520803A1 (en) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Novel uses
IL321252A (en) 2020-02-21 2025-08-01 Retrotope Inc Processes for isotopic alteration of polyunsaturated fatty acids and their derivatives
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US20070270429A1 (en) * 2003-05-06 2007-11-22 Shiro Shibayama Function Inhibitor of Effector Cell
RU2281085C2 (ru) * 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
KR20080034171A (ko) * 2005-07-28 2008-04-18 브리스톨-마이어스 스큅 컴퍼니 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌
US20100178277A1 (en) * 2007-05-25 2010-07-15 Medivation Neurology, Inc. Methods and compositions for stimulating cells

Also Published As

Publication number Publication date
CN102395275A (zh) 2012-03-28
WO2010068867A1 (en) 2010-06-17
CA2747235C (en) 2021-02-09
AU2009324495A1 (en) 2011-07-28
US20110268699A1 (en) 2011-11-03
IL213476A0 (en) 2011-07-31
CA2747235A1 (en) 2010-06-17
AU2009324495B2 (en) 2015-12-24
JP2012512165A (ja) 2012-05-31
EP2375900B1 (en) 2016-03-02
EP2375900A4 (en) 2012-05-02
EP2375900A1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
BRPI0922871A2 (pt) metodos para o tratamento da esclerose múltipla usando pirazinoindóis tetracíclicos
IL232222A0 (en) Methods for treating progressive multiple sclerosis
BRPI0908715A2 (pt) métodos para tratamento da psoríase
DK2361116T3 (da) Bestrålingsindretning
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2280672A4 (en) TEMPORARY OSTOMY DEVICE
BRPI0919116A2 (pt) método
BRPI0910854A2 (pt) métodos de tratamento
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0821981A2 (pt) Roda para trilhos
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
DK2313489T3 (da) Fremstillingsmetode
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0822730A2 (pt) Método para comutação ininterrupta
BRPI0919127A2 (pt) métodos para tratamento de água
DK2244628T3 (da) Patientdata-sensorapparat
PL2254850T3 (pl) Sposób jodowania związków aromatycznych
BRPI0914680A2 (pt) método para produção de dispositivos de distribuição
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI0911625A2 (pt) Métodos
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0917684A2 (pt) método terapêutico homeopático
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer
BRPI0916597A2 (pt) Método

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL